Please login to the form below
afamelanotide
This page shows the latest afamelanotide news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more
Scenesse (afamelanotide) has not been launched in the UK, but the company has stated that the cost of an implant will be £12, 020 (excluding VAT).
Latest news
-
Orphan drugs lead CHMP recommendations
Scenesse (afamelanotide), developed by Australian company Clinuvel Pharmaceuticals, was one of two orphan medicines for rare diseases recommended in the latest round of opinions from the Committee for Medicinal Products for
-
EMA wants to embed patient viewpoint within drug assessment
They will, however, not take part in any decision-making process. The first medicine to be included in the project is the orphan drug afamelanotide and its use to treatment a
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
